← Back to directory

Efstathios Kastritis

Researcher Next ID · RN-023975

Researcher · Medicine

Shinshu University

Matsumoto, Greece

Not currently recruitingFunding unknown
Works count
1,161
Citation count
41,633
H-index
84
i10-index
408

Research interests

Medicine
Biochemistry, Genetics and Molecular Biology
Multiple Myeloma Research and Treatments
Amyloidosis: Diagnosis, Treatment, Outcomes
Chronic Lymphocytic Leukemia Research
Protein Degradation and Inhibitors
Peptidase Inhibition and Analysis

Publications

  • Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis

    Trends in Molecular Medicine · 2022 · 10.1016/j.molmed.2022.04.007

  • Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

    Journal of Biomedical Science · 2021 · 10.1186/s12929-020-00703-5

  • Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

    New England Journal of Medicine · 2021 · 10.1056/nejmoa2028631

  • Emerging treatment strategies for COVID-19 infection

    Clinical and Experimental Medicine · 2020 · 10.1007/s10238-020-00671-y

  • Organ-specific manifestations of COVID-19 infection

    Clinical and Experimental Medicine · 2020 · 10.1007/s10238-020-00648-x

  • Hematological findings and complications of COVID ‐19

    American Journal of Hematology · 2020 · https://doi.org/10.1002/ajh.25829

  • International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Blood Cancer Journal · 2020 · 10.1038/s41408-020-00366-3

  • The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

    Nature Reviews Nephrology · 2018 · 10.1038/s41581-018-0077-4

  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

    New England Journal of Medicine · 2018 · 10.1056/nejmoa1802917

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Leukemia · 2017 · 10.1038/leu.2017.138

  • International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.65.0044

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

  • European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

    Haematologica · 2015 · https://doi.org/10.3324/haematol.2014.117176

  • Diagnosis of monoclonal gammopathy of renal significance

    Kidney International · 2015 · 10.1038/ki.2014.408

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

  • A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

    Blood · 2013 · 10.1182/blood-2012-12-473066

  • How I treat monoclonal gammopathy of renal significance (MGRS)

    Blood · 2013 · 10.1182/blood-2013-05-495929

  • Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop

    British Journal of Haematology · 2012 · 10.1111/bjh.12102

  • New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

    Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.37.7614

  • BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

    Cell · 2011 · https://doi.org/10.1016/j.cell.2011.08.017

  • Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis

    Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.23.8220

  • Pathogenesis and treatment of renal failure in multiple myeloma

    Leukemia · 2008 · 10.1038/leu.2008.131

  • Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

    Annals of Oncology · 2008 · 10.1093/annonc/mdn554

  • Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

    PubMed · 2006

  • Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors

    Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.02.8670

Current projects

    No projects listed.